Compare STOK & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | PLUS |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2019 | 1996 |
| Metric | STOK | PLUS |
|---|---|---|
| Price | $33.14 | $89.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $31.00 | N/A |
| AVG Volume (30 Days) | ★ 880.4K | 205.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.12% |
| EPS Growth | N/A | ★ 14.25 |
| EPS | 0.68 | ★ 4.60 |
| Revenue | $205,632,000.00 | ★ $2,285,906,000.00 |
| Revenue This Year | $430.24 | $14.37 |
| Revenue Next Year | N/A | $3.17 |
| P/E Ratio | $45.09 | ★ $19.44 |
| Revenue Growth | ★ 1128.17 | 9.24 |
| 52 Week Low | $5.35 | $53.83 |
| 52 Week High | $38.69 | $93.37 |
| Indicator | STOK | PLUS |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 61.31 |
| Support Level | $28.74 | $86.02 |
| Resistance Level | $31.44 | $90.75 |
| Average True Range (ATR) | 1.83 | 2.81 |
| MACD | 0.38 | -0.54 |
| Stochastic Oscillator | 95.76 | 48.57 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.